Introduction: Concern regarding the cardiotoxicity of antimalarials has been renewed because of their potential to cause QT/QTc interval prolongation related to torsade de pointes (TdP). Artemisinin-piperaquine (AP) is considered an effective artemisinin-based combination therapy (ACT) for malaria.
Methods: This study involved a retrospective analysis of clinical data of 93 hospitalized malaria patients who had received AP orally. Electrocardiograms (ECGs) were obtained at specific time points in the original study.
Results: Some cases of QT prolongation were observed. However, no TdP was found.
Conclusions: AP may cause QT interval prolongation in some malaria patients but may not lead to TdP.